Is argenx SE (NASDAQ:ARGX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating argenx SE at current levels.
VYVGART is becoming the autoimmune equivalent of a platform drug, and the pipeline behind it makes argenx a generational compounder.
Where ARGX is headed
argenx has stopped being a one-drug story and started behaving like a franchise. VYVGART is already approved in generalized myasthenia gravis, ITP, and CIDP, and the Sjögren's, myositis, and seronegative MG readouts coming through 2026 and 2027 are pushing the addressable patient pool from roughly 70,000 treated today toward something north of 400,000 by decade's end. Revenue grew 62.6% in the trailing twelve months, operating margin is already 30%, and management is guiding to a label expansion every twelve to eighteen months for the rest of the decade. This is what a biotech looks like when the science compounds before patent risk shows up.
Read the full Compass Direction on ARGX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $884.00).
See the full ARGX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is argenx SE (NASDAQ:ARGX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating argenx SE at current levels. VYVGART is becoming the autoimmune equivalent of a platform drug, and the pipeline behind it makes argenx a generational compounder.
What is ARGX's Compass Score?
argenx SE scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for ARGX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ARGX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.